The growth hormone - Insulin-like growth factor-I axis and colorectal cancer

Trends in Molecular Medicine

Volumn 7, Issue 10, 2001, Pages 447-454

  Bustin, Stephen A ^a   Jenkins, Paul J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AXIN; BETA CATENIN; CYCLOOXYGENASE 2; GHRELIN; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; MAD PROTEIN; MOTILIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOSTATIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACROMEGALY; ANGIOGENESIS; APOPTOSIS; AUTOCRINE EFFECT; CARCINOGENESIS; COLORECTAL CANCER; EPITHELIUM CELL; HUMAN; MITOGENESIS; ONCOGENE K RAS; REVIEW;

EID: 0034798719     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(01)02104-9     Document Type: Review

References (67)

1. The IGF-I receptor in cell growth, transformation and apoptosis
2. The somatomedin hypothesis: 2001
3. Autocrine and paracrine actions of intestinal fibroblast-derived insulin-like growth factors
4. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth
5. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
6. IGF-I and IGF-II in relation to colorectal cancer
7. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women
8. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women
9. Serum concentrations of insulin-like growth factor 1 in colonic neoplasia
10. More about: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
11. Alterations in serum levels of insulin-like growth factors and insulin- like growth-factor-binding proteins in patients with colorectal cancer 120
12. Increased levels of insulin-like growth factor binding protein-2 in sera and tumours from patients with colonic neoplasia with and without acromegaly
13. Acromegaly and cancer: A problem
14. Increased epithelial cell proliferation in the colon of patients with acromegaly
15. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly
16. Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of β-catenin/T-cell factor 4-mediated gene transactivation
17. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3β inhibition and Ras activation
18. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of β-catenin
19. Induction of transforming growth factor β 1 by insulin-like growth factor-1 in dermal fibroblasts
20. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor β (TGF-β): Conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta
21. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1
22. Down-regulation of TGF-beta receptors in human colorectal cancer: Implications for cancer development
23. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells
24. The role of cyclooxygenases in inflammation, cancer, and development
25. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells
26. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product
27. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas
28. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma
29. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I
30. The binding of bombesin and somatostatin and their analogs to human colon cancers
31. Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer
32. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers
33. Ghrelin is a growth-hormone-releasing acylated peptide from stomach
34. A receptor in pituitary and hypothalamus that functions in growth hormone release
35. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans
36. Growth hormone secretagogue binding sites in peripheral human tissues
37. Growth hormone-like material in normal human tissues
38. Growth hormone and colorectal carcinoma: Localization of receptors
39. The molecular basis of growth hormone action
40. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas
41. Insulin-like growth factors and their binding proteins in human colonocytes: Preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers
42. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon
43. Insulin-like growth factor I receptor messenger RNA in the colon is unchanged during neoplasia
44. Type I insulin-like growth factor receptors in human colorectal cancer
45. Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers
46. Expression of insulin-like growth factor-1 receptor in human colorectal cancer
47. Expression of IGFBP-2, -3, and -4 mRNA during differentiation of Caco-2 colon epithelial cells
48. Cell polarity of the insulin-like growth factor system in human intestinal epithelial cells. Unique apical sorting of insulin-like growth factor binding protein-6 in differentiated human colon cancer cells
49. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene
50. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells
51. Direct functional interactions between insulin-like growth factor- binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis
52. Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells
53. IGFBP-3 mediates TGF beta 1 proliferative response in colon cancer cells
54. The contradictions of the insulin-like growth factor 1 receptor
55. Differential requirements of the MAP kinase and PI3 kinase signaling pathways in Src- versus insulin and IGF-1 receptors-induced growth and transformation of rat intestinal epithelial cells
56. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha- induced mitogen-activated protein kinase and nuclear factor κB signaling pathways
57. Mirk protein kinase as a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells
58. Resection-induced colonic adaptation is augmented by IGF-I and associated with upregulation of colonic IGF-I mRNA
59. Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells
60. Cell receptors and cell signalling
61. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells
62. Up-regulation of insulin/insulin-like growth factor-I hybrid receptors during differentiation of HT29-D4 human colonic carcinoma cells
63. Insulin and insulin-like growth factor I receptors utilize different G protein signaling components
64. Insulin-like growth factor-I receptor internalization regulates signaling via the Shc/mitogen-activated protein kinase pathway, but not the insulin receptor substrate-1 pathway
65. Postmenopausal hormone use and risk of large-bowel cancer
66. Selective loss of estrogen receptor beta in malignant human colon
67. Growth hormone receptor antagonists: Potential indications